NCT00168870Unknown2 期
Randomized Phase II Study to Compare a Combination Therapy With Gemcitabine and Treosulfan Versus a Monotherapy as First-Line Chemotherapy for Patients With Metastatic Ocular Melanoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 48
- 试验地点
- 2
- 主要终点
- Determination of efficacy according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
研究概览
简要总结
This study evaluates treatment with combination versus monotherapy for patients with metastatic ocular melanoma.
详细描述
Treatment of patients with metastatic ocular melanoma with combination chemotherapy Gemcitabine and Treosulfan versus monotherapy with Treosulfan as first-line chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic ocular melanoma
排除标准
- •Prior treatment with chemotherapy
- •Active 2nd malignancy
- •Cerebral metastasis
结局指标
主要结局
Determination of efficacy according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
次要结局
- Time to progression
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and CarboplatinLung Cancer, Small CellNCT06698965Shanghai Chest Hospital52
招募中
不适用
Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumorocally recurrent or metastatic breast cancer patients with HER2/neu negative tumorNL-OMON20125VU University medical centerProf. E. Boven, MD, PhD, medical oncologistDe Boelelaan 11171081 HV AmsterdamPhone: 020-444 4336E-mail: e.boven@vumc.nltogether with:Borstkanker Onderzoek Groep(BOOG) Dr. A.E. van Leeuwen-Stok, research-managerP.O. Box 9236, 1006 AE AmsterdamPhone: 020-346 2547Fax: 020-346 2525E-mail: boog@ikca.nl312
已完成
2 期
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeNCT03662542Janssen Research & Development, LLC214
已完成
2 期
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant MesotheliomaAdvanced Malignant MesotheliomaEpithelial MesotheliomaLocalized Malignant MesotheliomaRecurrent Malignant MesotheliomaSarcomatous MesotheliomaNCT00027703National Cancer Institute (NCI)106
尚未招募
2 期
Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell CarcinomaOral Squamous Cell Carcinoma (OSCC)Oropharyngeal Squamous Cell Carcinoma (SCC)Resectable Oral and Oropharyngeal Squamous Cell CarcinomaRecurrent Oral and Oropharyngeal Squamous Cell CarcinomaNCT06728618Shanghai Zhongshan Hospital28